Arcus Biosciences Inc (RCUS)
15.56
+0.06
(+0.39%)
USD |
NYSE |
Nov 04, 16:00
15.55
-0.01
(-0.06%)
Pre-Market: 20:00
Arcus Biosciences Revenue (Quarterly): 39.00M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | 39.00M |
March 31, 2024 | 145.00M |
December 31, 2023 | 31.00M |
September 30, 2023 | 32.00M |
June 30, 2023 | 29.00M |
March 31, 2023 | 25.00M |
December 31, 2022 | 34.00M |
September 30, 2022 | 33.00M |
June 30, 2022 | 27.00M |
March 31, 2022 | 18.00M |
December 31, 2021 | 354.62M |
September 30, 2021 | 9.461M |
June 30, 2021 | 9.461M |
March 31, 2021 | 9.461M |
Date | Value |
---|---|
December 31, 2020 | 9.97M |
September 30, 2020 | 64.53M |
June 30, 2020 | 1.75M |
March 31, 2020 | 1.75M |
December 31, 2019 | 9.75M |
September 30, 2019 | 1.75M |
June 30, 2019 | 1.75M |
March 31, 2019 | 1.75M |
December 31, 2018 | 1.562M |
September 30, 2018 | 4.291M |
June 30, 2018 | 1.25M |
March 31, 2018 | 1.25M |
December 31, 2017 | 1.25M |
September 30, 2017 | 0.163M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
1.75M
Minimum
Mar 2020
354.62M
Maximum
Dec 2021
46.51M
Average
27.00M
Median
Jun 2022
Revenue (Quarterly) Benchmarks
Merck & Co Inc | 16.66B |
Intra-Cellular Therapies Inc | 175.16M |
Syndax Pharmaceuticals Inc | 3.50M |
Clearside Biomedical Inc | 0.09M |
Janux Therapeutics Inc | 8.897M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | -93.00M |
Total Expenses (Quarterly) | 145.00M |
EPS Diluted (Quarterly) | -1.02 |
Enterprise Value | 453.61M |
Profit Margin (Quarterly) | -238.5% |
Earnings Yield | -19.86% |
Normalized Earnings Yield | -18.37 |